newsfilter
← Latest News
ACCESS Newswire·

IGC Pharma to Host Mid-Year Fiscal 2026 Shareholder Update Call on November 17, 2025

  • IGC Pharma (NYSE: IGC) will host a conference call & webcast on Monday, November 17, 2025, at 11:00 a.m. Eastern Time to review operational progress for the second quarter & mid-year period ended September 30, 2025.
  • Participants can join by phone at (888) 506 0062 or international line (973) 528 0011 using access code 146922.
  • The live webcast is accessible via https://www.webcaster5.com/Webcast/Page/2938/53104, with a replay available until Thursday, February 12, 2026.
  • IGC Pharma is a clinical-stage biotechnology company using AI to develop treatments for Alzheimer's disease & metabolic disorders.
  • The company's lead asset, IGC-AD1, is a cannabinoid-based therapy currently in Phase 2 CALMA trials for agitation in Alzheimer's dementia.
  • The pipeline includes TGR-63 targeting amyloid plaques & early-stage programs focused on neurodegeneration, tau proteins, & metabolic dysfunctions.
  • IGC Pharma holds 12 granted patents & has filed more than 30 patents while integrating AI to accelerate drug discovery & optimize clinical trials.
  • The press release includes forward-looking statements subject to risks such as regulatory approval hurdles, AI algorithm performance, & general economic conditions.
  • Investor relations contact is Rosalyn Christian or John Nesbett at IMS Investor Relations via email at igc@imsinvestorrelations.com or phone at (203) 972-9200.